Ddp-225 free base anhydrous
As of the edition of 20 October 2026, Ddp-225 free base anhydrous is a small molecule: went quiet in 2007; acts on HTR3A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2007
- Kind
- Small molecule
- Registered trials
- 2, 1 stopped early
- Disease areas
- Digestive system; Inherited and neonatal; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Ddp-225 free base anhydrous.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HTR3A | 5-hydroxytryptamine receptor 3A | P46098 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 1 | 0 | 1 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Dynogen Pharmaceuticals | Lead sponsor of trials | 2005 to now |